AstraZeneca Corp. - רווח נקי למניה (EPS TTM) AZN

AstraZeneca PLC (AZN) is developing a high-tech treatment system for oncology and orphan diseases while facing pricing pressure from regulators. Manufacturing capacities are scaling through external contractors, necessitating rigorous quality control. Decarbonization and eco-friendly inhalers complement the ESG strategy. The company's net income per share over 12 months demonstrates financial resilience, where the value of 7.08 reflects this status.

For AstraZeneca PLC (AZN), whose returns rely on patent protection and the success of new oncology drugs, the rolling annual EPS chart reflects the actual efficiency of R&D investments. This indicator captures actual net income divided by the number of shares over the last 12 months, eliminating forecast subjectivity and smoothing reporting lags. This allows the investor to objectively assess the business trajectory and the asset's fundamental value.